Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine with anticonvulsant properties. It acts as a positive allosteric modulator of GABA-A receptors.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric and adult patients.
* Off-label uses may include other seizure types, anxiety, and movement disorders.
## Adult Dosing
* **Lennox-Gastaut Syndrome:** The recommended starting dose is 5 mg twice daily. The dose can be increased by 5-10 mg every week. The maximum recommended daily dose is 20 mg twice daily (40 mg total daily dose).
* Titrate to the lowest effective dose.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome:**
* **Patients 2 years and older:** The recommended starting dose is 5 mg twice daily. The dose can be increased by 5-10 mg every week. The maximum recommended daily dose is 10 mg twice daily (20 mg total daily dose).
* **Patients younger than 2 years:** Dosing in this age group is less established and requires careful titration and monitoring due to increased sensitivity to adverse effects. The starting dose is typically 2.5 mg once daily, with gradual increases based on clinical response and tolerability. Maximum daily dose is generally considered 5 mg twice daily (10 mg total daily dose), but this is highly individualized.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosing adjustments are universally established, but a lower starting dose and slower titration may be warranted.
* **Renal Impairment:** No specific dose adjustments are typically required, but caution is advised.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Acute narrow-angle glaucoma.
## Adverse Effects
* **Common:** Drowsiness, somnolence, fatigue, lethargy, ataxia, drooling, constipation, increased appetite, behavioral changes (irritability, aggression), rash.
* **Serious:** Suicidal ideation/behavior, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence, withdrawal symptoms, paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants:** Increased risk of sedation and respiratory depression (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines, antipsychotics).
* **CYP2C19 Inhibitors:** May increase clobazam levels (e.g., fluconazole, omeprazole).
* **CYP2C19 Inducers:** May decrease clobazam levels (e.g., rifampin).
* **Antiepileptic Drugs (AEDs):** Potential for altered levels or additive CNS depression.
## Monitoring
* Monitor for efficacy (seizure frequency, severity).
* Monitor for adverse effects, especially somnolence, behavioral changes, and signs of respiratory depression.
* Monitor for signs of rash and hypersensitivity reactions.
* Monitor for signs of withdrawal if abruptly discontinued.
* Regularly assess for suicidal ideation and behavior.
## Clinical Pearls
* Clobazam has a longer half-life than many other benzodiazepines, which can influence dosing frequency and withdrawal.
* Rash is a significant concern and may require discontinuation.
* Dose should be tapered slowly upon discontinuation to avoid withdrawal symptoms.
* Caution is advised when switching from other benzodiazepines or when combining with other CNS depressants.
* The 2 mg, 5 mg, and 10 mg oral suspension formulations are commonly used in pediatrics and for titration in adults.
***
*Disclaimer: This information is intended for clinical use and does not replace professional medical advice. Always refer to the most current prescribing information and institutional protocols for definitive patient management.*
